Targeting CD38 to improve imaging of multiple myeloma
CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS
['FUNDING_R01'] · HOAG MEMORIAL HOSPITAL PRESBYTERIAN · NIH-10918289
This study is testing a new imaging technique to help people with multiple myeloma see how much of the cancer is in their body, which could lead to better treatment choices and monitoring.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | HOAG MEMORIAL HOSPITAL PRESBYTERIAN (nih funded) |
| Locations | 1 site (NEWPORT BEACH, UNITED STATES) |
| Trial ID | NIH-10918289 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the imaging of multiple myeloma, a type of blood cancer, using a specialized technique called CD38-targeted immunoPET. By utilizing a radiolabeled monoclonal antibody, the study aims to visualize the disease burden in patients more effectively than current methods. The trial will assess how well this imaging correlates with standard laboratory tests and imaging techniques, potentially leading to better treatment decisions and monitoring. Patients with multiple myeloma may benefit from this innovative approach that seeks to provide a clearer picture of their disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple myeloma who are undergoing treatment or monitoring.
Not a fit: Patients with other types of blood cancers or those not diagnosed with multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate assessments of multiple myeloma, improving treatment strategies and patient outcomes.
How similar studies have performed: Previous studies using targeted imaging techniques have shown promise in improving disease visualization, suggesting a potential for success in this novel approach.
Where this research is happening
NEWPORT BEACH, UNITED STATES
- HOAG MEMORIAL HOSPITAL PRESBYTERIAN — NEWPORT BEACH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ULANER, GARY ALLAN — HOAG MEMORIAL HOSPITAL PRESBYTERIAN
- Study coordinator: ULANER, GARY ALLAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Detectable Residual Disease, Detection of Minimal Residual Disease